Results 121 to 130 of about 25,929 (279)

Hitting histone demethylases [PDF]

open access: yesScience-Business eXchange, 2012
A GSK–Structural Genomics Consortium team has identified the first potent and selective histone demethylase inhibitor and shown that the molecule dampens the macrophage inflammatory response. The pharma now is focusing on internal efforts and external approaches to exploring potential therapeutic applications of the inhibitor.
openaire   +1 more source

Structure-function relationships in KDM7 histone demethylases.

open access: yes, 2019
The demethylation of lysine residues of histone proteins is a key epigenetic mechanism in cells. The enzymes that catalyze these processes are called histone demethylases (KDMs).
Chaturvedi, Shobhit   +4 more
core   +1 more source

The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance [PDF]

open access: yes, 2019
KDM4/JMJD2 are H3K9- and H3K36-specific demethylases, which are considered promising therapeutic targets for the treatment of acute myeloid leukemia (AML) harboring MLL translocations. Here, we investigate the long-term effects of depleting KDM4 activity
Messling, Jan-Erik   +5 more
core   +1 more source

β‐Aminoisobutyric Acid Alleviates Cisplatin‐Induced Muscle Atrophy by Regulating E3 Ubiquitin Ligases, Apoptosis, Amino Acid Metabolism, Autophagy, and Ferroptosis

open access: yesMedicine Bulletin, EarlyView.
ABSTRACT Background Cisplatin (CIS) is a widely used broad‐spectrum anticancer agent, but its clinical application is often limited by severe adverse effects, including skeletal muscle atrophy, which compromises patients' quality of life and treatment efficacy.
Hao‐Zhe Wang   +10 more
wiley   +1 more source

KMT5C‐Mediated H4K20me3 Recruits EWSR1 to Propel Clear Cell Renal Cell Carcinoma Progression via Regulating ACADM Transcription and m6A Modification

open access: yesMed Research, EarlyView.
A schematic diagram illustrating the KMT5C‐H4K20me3‐EWSR1‐ACADM signaling axis and its role in ccRCC progression. Key Outcomes: KMT5C/H4K20me3 are upregulated in ccRCC and predict poor prognosis. EWSR1 is a novel noncanonical H4K20me3 reader in ccRCC. KMT5C/EWSR1 co‐repress ACADM via transcription and m6A modification. A‐196 + sunitinib synergistically
Chengjian Ji   +10 more
wiley   +1 more source

Identification of Histone Demethylases in Saccharomyces Cerevisiae

open access: yes, 2008
Based on the prediction that histone lysine demethylases may contain the JmjC domain, we examined the methylation patterns of five knock-out strains (ecm5 Delta, gis1 Delta, rph1 Delta, jhd1 Delta, and jhd2 Delta ( yjr119c Delta)) of Saccharomyces ...
羅椀升;蔡明道   +1 more
core  

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

open access: yesPrecision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik   +4 more
wiley   +1 more source

Structure Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases

open access: yes, 2019
Human histone demethylases are known to play an important role in the development of several tumor types. Consequently, they have emerged as important medical targets for the treatment of human cancer.
Malecki, P.H.   +24 more
core   +1 more source

The continuing significance of chiral agrochemicals

open access: yesPest Management Science, Volume 81, Issue 4, Page 1697-1716, April 2025.
In the time frame 2018–2023, around 43% of the 35 chiral agrochemicals introduced to the market (herbicides, fungicides, insecticides, acaricides, and nematicides) contain one or more stereogenic centers in the molecule, and almost 69% of them have been marketed as racemic mixtures of enantiomers or stereoisomers.
Peter Jeschke
wiley   +1 more source

Assays and Inhibitors for JumonjiC Domain-Containing Histone Demethylases as Epigenetic Regulators

open access: yes, 2016
JumonjiC domain-containing histone demethylases (JMJC demethylases) are epigenetic "eraser" enzymes that oxidatively remove methyl marks from the epsilon-amino groups of histone lysine residues in an iron(II)- and 2-oxoglutarate-dependent mechanism ...
Roatsch, Martin
core   +1 more source

Home - About - Disclaimer - Privacy